IL17A and psoriasis: Similar to secukinumab, around 80% to 90% of patients treated with ixekizumab [88, 89] and brodalumab [90, 91] achieved a PASI75 response, indicating that the IL-17 pathway is critical for keratinocytes and infiltrating immune cells in the skin of psoriasis.